Dec 21, 2017 · Throughout the course of treatment, many patients with cancer receive chemotherapy, intravenous fluids, antibiotics, and much more via central venous catheters such as Mediports.

Sep 3, 2024 · Throughout the month of August, several cancer therapies have been approved by the FDA for diseases including non-small cell lung cancer (NSCLC), cutaneous T-cell lymphoma, astrocytoma and oligodendroglioma, and endometrial cancer.

Dec 18, 2024 · “ctDNA testing looks for small pieces of DNA found in a patient’s blood that comes from cancer cells and tumors,” Grafton explains. “Screening for ctDNA can be used to detect cancer early, before symptoms occur, and also to monitor tumor growth in cases where cancer has already been detected.”

Sep 23, 2024 · During an episode of of The Vitals, Jessica Fox, RN, a radiation oncology nurse with the Providence Cancer Institute in Portland, Oregon, discussed some of radiation’s common adverse effects (AEs) for patients with prostate cancer, including irritable bowel symptoms; urinary urgency, frequency, and burning; erectile dysfunction; ejaculatory change; and fatigue.

Oct 24, 2024 · The American Society of Clinical Oncology (ASCO) recently announced guidelines outlining a preference for abemaciclib (Verzenio) over ribociclib (Kisqali) for the treatment of patients with node-positive, high-risk, hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. 1. The recommendation is based on findings from the monarchE (NCT03155997 ...

Dec 27, 2024 · The FDA has approved tislelizumab-jsgr (Tevimbra) for use with platinum- and fluoropyrimidine-based chemotherapy in the first-line setting for unresectable or metastatic, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (≥1). 1,2 The regulatory decision was supported by data from the phase 3 RATIONALE-305 trial (NCT03777657), which showed ...

Jul 1, 2024 · Throughout the month of June, several cancer therapies have received FDA approval for diseases including thyroid cancer, myelodysplastic syndrome (MDS), colorectal cancer (CRC), endometrial cancer, and follicular lymphoma (FL).

Jul 10, 2024 · CAR T-cell therapy represents a significant advancement in the treatment of multiple myeloma, especially as its ability to provide deep and durable responses offers renewed hope to patients and healthcare providers alike, an expert said.

Oct 7, 2024 · Panelists discuss how axatilimab, a novel therapy for chronic graft-versus-host disease (cGVHD), functions through a unique mechanism of action compared to other treatments, highlighting its potential role in cGVHD management and presenting key findings from the AGAVE-201 trial that demonstrate its efficacy and safety profile.

Dec 9, 2024 · Compared with active monitoring, subcutaneous daratumumab (Darzalex Faspro) led to significant progression-free survival (PFS) benefit in patients with intermediate- or high-risk smoldering multiple myeloma, according to primary results from the phase 3 AQUILA study (NCT03301220). 1-2 Further, the greatest PFS benefit was …